A5088296082- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Monoclonal and Polyclonal Antibodies Research
- Estrogen and related hormone effects
- Immunotherapy and Immune Responses
- Radiomics and Machine Learning in Medical Imaging
- Extracellular vesicles in disease
- Urinary and Genital Oncology Studies
- Gastric Cancer Management and Outcomes
- Proteoglycans and glycosaminoglycans research
- Neuroendocrine Tumor Research Advances
- Lymphoma Diagnosis and Treatment
- Breast Lesions and Carcinomas
- Renal and related cancers
- Bladder and Urothelial Cancer Treatments
- interferon and immune responses
- Immune cells in cancer
- Cancer Genomics and Diagnostics
- Cell Adhesion Molecules Research
- Wnt/β-catenin signaling in development and cancer
- Lung Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Metabolism, Diabetes, and Cancer
Menoufia University
2013-2025
University of Birmingham
2018-2024
Genomics (United Kingdom)
2019-2022
Queen Elizabeth Hospital Birmingham
2021
The response of human epidermal growth factor receptor2 (HER2)- positive breast cancer (BC) patients to anti-HER2 targeted therapy is significant. However, the not uniform and a proportion HER2-positive do respond. This study aims identify predictors in neoadjuvant treatment assess discordance rate HER2 status between pre- post-treatment specimens BC patients. group comprised 500 treated with chemotherapy (NACT) and/or surgery who had tumours that were 3+ or 2+ immunohistochemistry (IHC)....
The immune microenvironment in breast cancer (BCa) is controlled by a complex network of communication between various cell types. Here, we find that recruitment B lymphocytes to BCa tissues via mechanisms associated with cell-derived extracellular vesicles (CCD-EVs). Gene expression profiling identifies the Liver X receptor (LXR)-dependent transcriptional as key pathway controls both CCD-EVs-induced migration cells and accumulation tissues. increased oxysterol ligands for LXR (i.e.,...
While there are fast advances in the detection and management of bladder carcinoma, number deaths remains high. Therefore, identification an effective biomarker predicting tumor progression cancer patients is a crucial issue. This study aimed to identify TIPE2 CD36 expressions examine their relationship with clinicopathological data prognosis. Using immunohistochemistry, 60 specimens urothelial (UC) for expression were studied compared clinicopathologic parameters survival data. Furthermore,...
There are limited data on the role of multigene tests and their correlation with immunohistochemistry (IHC), especially core biopsy. MammaTyper is a quantitative conformite Europeeanne (CE) marked, National Institute for Health Care excellence (NICE) approved, in vitro diagnostic real-time polymerase chain reaction (RT-qPCR) test assessment mRNA expression four biomarkers (ESR1, PGR, ERBB2, MKI67).
The assessment of PD-L1 expression in TNBC is a prerequisite for selecting patients immunotherapy. accurate pivotal, but the data suggest poor reproducibility. A total 100 core biopsies were stained using VENTANA Roche SP142 assay, scanned and scored by 12 pathologists. Absolute agreement, consensus scoring, Cohen's Kappa intraclass correlation coefficient (ICC) assessed. second scoring round after washout period to assess intra-observer agreement was carried out. occurred 52% 60% cases...
Abstract The immune microenvironment in inflammatory breast cancer (IBC) is poorly characterised, and molecular cellular pathways that control accumulation of various cells IBC tissues remain largely unknown. Here, we discovered a novel pathway linking the expression tetraspanin protein CD151 tumour with increased macrophages cancerous tissues. It notable elevated higher number tumour‐infiltrating correlated better patient responses to chemotherapy. Accordingly, CD151‐expressing xenografts...
Abstract Background The ASCO/CAP guidance on HER2 testing in breast cancer (BC) has recently changed. Group 2 tumours with immunohistochemistry score 2+ and / CEP17 ratio ≥2.0 copy number <4.0 signals/cell were re-classified as negative. This study aims to examine the response of neoadjuvant chemotherapy (NACT). Methods 749 BC cases identified from 11 institutions. association between groups pathological complete (pCR) was assessed. Results 54% positive (score 3+) BCs showed pCR, compared...
Introduction: Inflammatory breast cancer (IBC) is an aggressive form of with a poorly characterized immune microenvironment. Methods: We used five-colour multiplex immunofluorescence panel, including CD68, CD4, CD8, CD20, and FOXP3 for microenvironment profiling in 93 treatment-naïve IBC samples. Results: Lower grade tumours were by decreased CD4+ cells but increased accumulation FOXP3+ cells. Increased CD20+ correlated better response to neoadjuvant chemotherapy infiltration overall...
Tumor-associated macrophages (TAMs) and dendritic cells (DCs) may play a role in tumor progression as part of the microenvironment many neoplasms, including those Hodgkin's lymphoma. The current study investigated relationship between presence density background classic lymphoma (CHL) different clinicopathological parameters, survival response to therapy. CD68 CD1a immunohistochemical staining were used detect highlight cells, respectively, 61 cases CHL. was expressed all studied cases, with...
Oestrogen receptor (ER)-positive breast cancer (BC) is generally well responsive to endocrine therapy. Neoadjuvant therapy (NAET) increasingly being used for downstaging ER-positive tumours. This study aims analyse the effect of NAET on a well-characterised cohort BC with particular emphasis expression. retrospective United Kingdom (UK) multicentre 391 patients who received between October 2012 and 2020. Detailed analyses paired pre- post-NAET morphological changes hormone (HR) human...
Extramedullary haematopoiesis (EMH) in the axillary lymph node of breast cancer patients is extremely rare but when encountered can represent a diagnostic challenge. We aim to highlight this incidental finding as pitfall which be mistaken for metastatic carcinoma (particularly metaplastic type). report case 68-year-old Caucasian female with family history cancer. Core biopsy revealed that she had grade II oestrogen receptor-negative, Her2-positive invasive ductal carcinoma. She was offered...
Neoadjuvant endocrine therapy (NAET) is used in the management of oestrogen receptor (ER)-positive breast cancer. The optimal method for histological assessment response and effect NAET on tumour morphology, grade molecular profile remain unclear. aim this study to investigate type, by analysing a well-characterised cohort cancer samples single large UK tertiary referral centre, provide guidance pathological those lesions inform adjuvant prognosis.A large-institution 132 patients who...
Androgen receptor (AR) is one of the predominant nuclear hormone receptors in invasive breast cancer and can be explored as a biomarker response for targeted anti-androgen therapy, especially setting triple negative (TNBC). Luminal AR distinct subtype amongst TNBC cases following gene expression studies. higher Africans (23%-82%) African-Americans (29.8%) compared to Caucasian (10%-15%) patients; however, there paucity data on this population. The aim study determine proportion positive...
Background The gene Parkin-induced protein kinase 1 (PINK1) encodes a serine/threonine associated with mitophagy. It is found in the mitochondria and protects cells against stress-related mitochondrial malfunction. However, its precise function development evolution of tumours, particularly breast cancer (BC), yet unknown. PINK1 immunohistochemistry expression invasive duct BC focus current study to link this several clinicopathological criteria, such as patient overall survival. Methods...